Oruka's ORKA-001 achieves complete skin clearance in 61% of high-dose patients in Phase 2b psoriasis trial
Bitget2026/10/26 11:05- Oruka Therapeutics announced positive Phase 2b EVERLAST-B results for ORKA-001 in moderate-to-severe plaque psoriasis, supporting planned Phase 3 development.
- The highest dose produced complete skin clearance in most patients, with results consistent with the earlier EVERLAST-A trial.
- Treatment was well tolerated, with no serious treatment-emergent adverse events in the high-dose group.
- Phase 3 trials are planned for the first half of 2027, pending regulatory discussions.
- Longer-term results are expected from EVERLAST-A in December 2026, followed by EVERLAST-B in the second half of 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.
AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
Tom Lee Says Democratic Sweep Could Fuel 15% to 20% Tech Rally
Crypto prices
More
